Innovative therapeutics

Products/
Pipeline

Products and Pipeline Overview

BioMarin has developed and commercialized a growing list of innovative biopharmaceuticals for rare diseases driven by genetic causes since 1997, a testament to the company’s passion and dedication to patients with serious unmet medical needs.

Products on the Market

BioMarin has five marketed products on the market today:

  • Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA)
  • Kuvan® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for PKU
  • Naglazyme® (galsulfase) for MPS VI
  • Aldurazyme® (laronidase) for MPS I
  • Firdapse® (amifampridine phosphate) (currently approved in the EU only) for LEMS

For full prescribing information, please visit www.vimizim.com, www.kuvan.com, www.naglazyme.com, and www.aldurazyme.com.

learn more

Vimizim
Click here to learn more about Vimizim (elosulfase alfa), including full prescribing information and boxed warning.

prod2
Click here to learn more about Naglazyme (galsulfase), including full prescribing information.

prod3
Click here to learn more about Aldurazyme (laronidase),
including full prescribing information and black box warning.

prod1
Click here to learn more about Kuvan (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution, including full prescribing information.

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information

Top